JP2025179094A5 - - Google Patents
Info
- Publication number
- JP2025179094A5 JP2025179094A5 JP2025138920A JP2025138920A JP2025179094A5 JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5 JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- morpholinophenyl
- ylamino
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US63/009,623 | 2020-04-14 | ||
| US202063014277P | 2020-04-23 | 2020-04-23 | |
| US63/014,277 | 2020-04-23 | ||
| PCT/IB2021/053035 WO2021209893A1 (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| JP2022562451A JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Division JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025179094A JP2025179094A (ja) | 2025-12-09 |
| JP2025179094A5 true JP2025179094A5 (enExample) | 2025-12-16 |
Family
ID=75562794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Active JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
| JP2025138920A Pending JP2025179094A (ja) | 2020-04-14 | 2025-08-22 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Active JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12138351B2 (enExample) |
| EP (1) | EP4135669A1 (enExample) |
| JP (2) | JP7787824B2 (enExample) |
| KR (1) | KR20230002656A (enExample) |
| CN (1) | CN115484937A (enExample) |
| AU (2) | AU2021257662B2 (enExample) |
| CA (1) | CA3180184A1 (enExample) |
| IL (1) | IL297240A (enExample) |
| MX (1) | MX2022012898A (enExample) |
| PH (1) | PH12022552454A1 (enExample) |
| TW (1) | TW202207940A (enExample) |
| UY (1) | UY39171A (enExample) |
| WO (1) | WO2021209893A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| US20240270733A1 (en) * | 2021-06-01 | 2024-08-15 | Hangzhou Solipharma Co., Ltd. | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| US6399591B1 (en) | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| WO2008057267A2 (en) * | 2006-10-27 | 2008-05-15 | Fmc Corporation | Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| ES2713330T3 (es) | 2009-12-11 | 2019-05-21 | Sumitomo Dainippon Pharma Co Ltd | Comprimido recubierto en seco que se desintegra oralmente |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| AU2013347962B2 (en) | 2012-11-21 | 2018-10-25 | Janssen Biotech, Inc. | Bispecific EGFR/c-Met antibodies |
| WO2015006752A1 (en) * | 2013-07-12 | 2015-01-15 | The Regents Of The University Of California | Combination therapies for malaria |
| UA120428C2 (uk) | 2013-12-12 | 2019-12-10 | Алміралл, С.А. | Фармацевтичні композиції, які містять диметилфумарат |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| MX2017003181A (es) | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
| TWI808938B (zh) | 2016-04-07 | 2023-07-21 | 美商卡默森屈有限公司 | 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷 |
| MX389966B (es) * | 2017-01-20 | 2025-03-20 | Exelixis Inc | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
| EP3592338A1 (en) * | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MX393995B (es) | 2017-07-28 | 2025-03-24 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina |
| DK3658553T3 (da) | 2017-07-28 | 2022-07-25 | Yuhan Corp | Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf |
| CN111295381A (zh) | 2017-07-28 | 2020-06-16 | 株式会社柳韩洋行 | 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法 |
| CN110580014B (zh) * | 2018-06-11 | 2021-03-30 | 北京京东尚科信息技术有限公司 | 用于控制自动导引运输车的方法、装置和系统 |
| WO2020018928A1 (en) | 2018-07-20 | 2020-01-23 | Imerys Usa, Inc. | Recovering sand, bentonite and organics from foundry sand waste |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| SG11202110585SA (en) | 2019-04-11 | 2021-10-28 | Goldfinch Bio Inc | Spray-dried formulation of a pyridazinone trpc5 inhibitor |
| EP4268815A3 (en) | 2019-04-17 | 2024-02-21 | NordicCan A/S | Fast disintegrating cannabinoid tablets |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| CA3144840A1 (en) | 2019-07-31 | 2021-02-04 | Leonie Flurina Claude Wagner-Hattler | New pharmaceutical formulation |
-
2021
- 2021-04-12 TW TW110113031A patent/TW202207940A/zh unknown
- 2021-04-13 PH PH1/2022/552454A patent/PH12022552454A1/en unknown
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Pending
- 2021-04-13 US US17/228,753 patent/US12138351B2/en active Active
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
- 2021-04-13 JP JP2022562451A patent/JP7787824B2/ja active Active
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en not_active Ceased
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 AU AU2021257662A patent/AU2021257662B2/en active Active
-
2024
- 2024-11-07 US US18/939,761 patent/US20250177311A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203347A patent/AU2025203347A1/en active Pending
- 2025-08-22 JP JP2025138920A patent/JP2025179094A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025179094A5 (enExample) | ||
| US8673945B2 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
| US20160129008A1 (en) | Solid Dosage Form of Olmesartan Medoxomil and Amlodipine | |
| US20190030033A1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| US20220211705A1 (en) | Pharmaceutical compositions comprising afatinib | |
| HRP20040403A2 (en) | Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same | |
| FI3866767T3 (fi) | Aminopyrimidiinijohdannaista tai sen suolaa käsittävä farmaseuttinen koostumus suun kautta annostelua varten | |
| JP2014074067A (ja) | メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形 | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| TWI574690B (zh) | 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 | |
| US6001845A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| UA69441C2 (uk) | Саредутант як агент для лікування або попередження основних депресивних розладів | |
| FI3993777T3 (fi) | Kompressoidut masitentaanikoostumukset, menetelmät ja niiden käytöt | |
| US6136818A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| CN102836161A (zh) | 一种以奥美沙坦酯与苯磺酸氨氯地平及氢氯噻嗪混合组成的药物的复方制剂 | |
| JPH05194228A (ja) | ダピプラゾール含有経口投与用固体医薬組成物 | |
| WO2013100870A1 (en) | New antipsychotic compositions | |
| JP7437039B2 (ja) | 錠剤 | |
| JP2024090218A (ja) | 崩壊遅延を改善したゾニサミド含有口腔内速崩壊錠 | |
| JP6939228B2 (ja) | 口腔内崩壊錠の製造方法 | |
| JP2022097443A (ja) | ビラスチンを含有する口腔内崩壊錠 | |
| GB2471970A (en) | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide | |
| NZ774402B2 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| KR20160014618A (ko) | 유기산과의 아고멜라틴 공-결정체 형태로 아고멜라틴을 포함하는 약제학적 제형 | |
| EP4420658A1 (en) | A film coated tablet comprising empagliflozin |